Ankylosing spondylitis: In clinical practice

Ankylosing Spondylitis: In Clinical Practice

Volumn , Issue , 2011, Pages 1-83

  Sieper, Joachim ^a   Braun, Jürgen ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Centre of Rheumatology Ruhrgebiet   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892073268     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-85729-180-6     Document Type: Book

References (104)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
2. Van Der Linden S, Valkenburg HA, et al. evaluation of diagnostic criteria for ankylosing spondylitis. a proposal for modification of the new york criteria. Arthritis Rheum 1984;27:361-8.
3. Braun J, Bollow M, et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039-45.
4. Rudwaleit M, Khan MA, et al. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000-8.
5. Dougados M, Van Der Linden S, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
6. Amor B, Dougados M, et al. [Criteria of the classification of spondylarthropathies]. Rev rhum mal osteoartic 1990;57:85-9.
7. Rudwaleit M, Van Der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (Part II): validation and final selection. Ann Rheum Dis 2009;68:770-6.
8. Feldtkeller E, Bruckel J, et al. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr opin Rheumatol 2000;12:239-47.
9. Rudwaleit M, Haibel H, et al. The early disease stage in axial spondyloarthritis. Results from the German spondyloarthritis inception cohort. Arthritis Rheum 2009;60:717-27.
10. Calin A, Fries JF. striking prevalence of ankylosing spondylitis in 'healthy' w27 positive males and females. N Engl J Med 1975;293:835-9.
11. Van Der Linden S, Valkenburg HA, et al. the risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241-9.
12. Braun J, Listing J, et al. Reply. Arthritis Rheum 2005;52:4049-59.
13. Gran T, Husby G, et al. Prevalence of ankylosing spondylitis in males and females in a young middle aged population in Tromso, northern Norway. Ann Rheum Dis 1985;44:359-67.
14. Gofton J P, Robinson HS, et al. Ankylosing spondylitis in a Canadian Indian population. Ann Rheum Dis 1966;25:525-7.
15. Saraux A, Guillemin F, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005;64:1431-5.
16. Guillemin F, Saraux A, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005;64:1427-30.
17. Adomaviciute D, Pileckyte M, et al. Prevalence survey of rheumatoid arthritis and spondyloarthropathy in Lithuania. Scand J Rheumatol 2008;37:113-19.
18. Helmick CG, Felson DT, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25.
19. Sieper J, Rudwaleit M, et al. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 2006;20:401-17.
20. Brewerton DA, Hart FD, et al. Ankylosing spondylitis and HLA-27. Lancet 1973; i: 904-7.
21. Sieper J, Braun J, et al. Report on the fourth international workshop on reactive arthritis. Arthritis Rheum 2000;43:720-34.
22. Maksymowych WP. ankylosing spondylitis - at the interface of bone and cartilage. J Rheumatol 2000;27:2295-301.
23. Appel H, Kuhne M, et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006;54:1805-13.
24. Sieper J, Appel H, et al. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008;58:649-56.
25. Appel H, Sieper J. Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics. Curr Rheumatol Rep 2008;10:356-63.
26. Maksymowych WP, Chiowchanwisawakit P, et al. inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93-102.
27. Brown MA, Kennedy LG, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997;40:1823-8.
28. Burton PR, Clayton DG, et al. Association scan of 14, 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-37.
29. Brown MA, Laval SH, et al. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis 2000;59:883-6.
30. Calin A, Porta J, et al. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977;237:2613-4.
31. Sieper J, Van Der Heijde D, et al. New criteria for inflammatory back pain in patients with chronic back pain - a real patient exercise of the Assessment in SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009;68:748-8.
32. Rudwaleit M, Metter A, et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006;54:569-78.
33. Rudwaleit M, Van Der Heijde D, et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004;63:535-43.
34. Baraliakos X, Listing J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007;66:910-5.
35. Landewe R, Dougados M, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009;68:863-7.
36. Van Der Cruyssen B, Ribbens C, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007;66:1072-7.
37. Mcgonagle D, Gibbon W, et al. characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998;41:694-700.
38. Lambert RG, Dhillon SS, et al. High prevalence of symptomatic enthesiopathy of the shoulder in ankylosing spondylitis: deltoid origin involvement constitutes a hallmark of disease. Arthritis Rheum 2004;51:681-90.
39. Zeboulon N, Dougados M, et al. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008;67:955-9.
40. Verstappen SM, Jacobs JW, et al. utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann Rheum Dis 2007;66:727-31.
41. Burgos-Vargas R, Vazquez-Mellado J. the early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 1995;38:835-44.
42. Bennett PH, Burch TA (eds.). Population studies of the rheumatic diseases. Amsterdam: Excerpta Medica Foundation, International Congress Series 1966, 148:456-7.
43. Rudwaleit M, Jurik AG, et al. The Assessment in SpondyloArthritis international Society (ASAS) definition of sacroiliitis on magnetic resonance imaging (MRI) - a consensual approach. Ann Rheum Dis 2009;68:1520-7.
44. Bennett AN, McGonagle D, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008;58:3413-18.
45. Underwood MR, Dawes P. Inflammatory back pain in primary care. Br J Rheumatol 1995;34:1074-7.
46. Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis 2005;64:659-63.
47. Brandt HC, Spiller I, et al. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 2007;66:1479-84.
48. Baraliakos X, Listing J, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor and antibody infliximab. Ann Rheum Dis 2005;64:1462-1466.
49. Vosse D, Landewe R, et al. ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case control study. Ann Rheum Dis 2009;68:1839-42.
50. Sieper J. Management of ankylosing spondylitis. In: Rheumatology, 4th edition. Edited by MC Hochberg, AJ Silman, et al. London: Mosby, 2008;1159.
51. Sieper J, Rudwaleit M, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis; 68 Suppl 2: ii1-44.
52. Braun J, Bollow M, et al. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:697-735.
53. Song IH, Carrasco-Fernandez J, et al. The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 2008;67:1535-40.
54. Zochling J, Van Der Heijde D, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
55. Anderson JJ, Baron G, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
56. Song IH, Poddubnyy DA, et al. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal anti-inflammatory drugs. Arthritis Rheum 2008;58:929-38.
57. Amor B, Dougados M, et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rheum Engl Ed 1995;62:10-15.
58. Gossec L, Dougados M, et al. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis 2008;67:782-8.
59. Wanders A, Heijde D, et al. nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
60. Braun J, Bollow M, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 1996;23:659-64.
61. Haibel H, Rudwaleit M, et al. open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005;64:296-8.
62. Haibel H, M. Rudwaleit, et al. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005;64:124-6.
63. Haibel H, Brandt HC, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007;66:419-21.
64. Dougados M, Van Der Linden S, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
65. Braun J, Zochling J, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006;65:1147-53.
66. Haibel H, Brandt HC, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007;66:419-21.
67. Brandt J, Listing J, et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
68. Van Der Heijde D, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
69. Van Der Heijde D, Kivitz A, et al. Adalimumab therapy results in significant reduction of signs and symptoms in subjects with ankylosing spondylitis: the ATLAS trial. Arthritis Rheum 2006;54 2136-46.
70. Davis JC, Van Der Heijde DM, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-62.
71. Braun J, Brandt J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
72. Davis JC Jr, Van Der Heijde D, et al. recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
73. Van Der Heijde D, Lie E, et al. The ASDAS is a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2008;68:1811-8.
74. Braun J, Landewe R, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
75. Rudwaleit M, Baraliakos X, et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005;64:1305-10.
76. Lambert RG, Salonen D, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007;56:4005-14.
77. Sieper J, Baraliakos X, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. rheumatology (oxford) 2005;44:1525-30.
78. Heiberg MS, Nordvag BY, et al. the comparative effectiveness of tumor necrosis factorblocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005;52:2506-12.
79. Braun J, Deodhar A, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008;59:1270-8.
80. Van Der Heijde D, Landewe R, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
81. Van Der Heijde D, Landewe R, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.
82. Braun J, Sieper J. What is the most important outcome parameter in ankylosing spondylitis? rheumatology (oxford) 2008;47:1738-40.
83. Breban M, Ravaud P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008;58:88-97.
84. Li EK, Griffith JF, et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. rheumatology (oxford) 2008;47:1358-63.
85. Braun J, Baraliakos X, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47.
86. Van Der Heijde D, Schiff MH, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2008;68(6):922-9.
87. Braun J, Baraliakos X, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51.
88. Rudwaleit M, Rodevand E, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2008;68:696-701.
89. Braun J, Baraliakos X, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67; 340-5.
90. Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of infliximab in patients with ankylosing spondylitis over 7 years - evidence for different response to anti-TNF-A therapy. Presented at: EULAR, the Annual European Congress of Rheumatology, Paris, France; June 11-14, 2008; FR10290.
91. Keat A, Barkham N, et al. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. rheumatology (oxford) 2005;44:939-47.
92. Maksymowych WP, Gladman D, et al. the canadian rheumatology association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol 2007;34:2273-84.
93. Braun J, Davis J, et al. asas Working group. First update of the international asas consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
94. Rudwaleit M, Listing J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
95. Haibel H, Rudwaleit M, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58:1981-91.
96. Rudwaleit M, Schwarzlose S, et al. MRI in predicting a major clinical response to antitumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008;67:1276-81.
97. Amor B, Santos RS, et al. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994;21:1883-7.
98. Barkham N, Keen H, et al. A randomised controlled trial of infliximab shows clinical and MRI efficacy in patients with HLA-B27 positive very early ankylosing spondylitis. Presented at: 71st annual scientific meeting of the American College of Rheumatology. Boston, Massachusetts; November 6-11, 2007;
99. Arthritis Rheum 2009 Apr; 60(4):946-54.
100. Garrett S, Jenkinson T, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
101. Van Der Heijde D, Calin A, et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the asas Working group. assessments in ankylosing spondylitis. J rheumatol 1999;26:951-4.
102. Calin A, Garrett S, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
103. Boonen A, Van Der Heijde D, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006;65:201-8.
104. Kobelt G, Sobocki P, et al. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data. Scand J Rheumatol 2008;37:62-71.